Quotes 5-day view Delayed Nasdaq
11/29/2021
11/30/2021
12/01/2021
12/02/2021
12/03/2021
Date
654.4(c)
636.53(c)
630.59(c)
634(c)
635.16(c)
Last
700 393
1 277 301
732 074
563 827
637 304
Volume
+1.72% -2.73% -0.93% +0.54% +0.18% Change
Estimated financial data (e) (USD)
Sales 2021
15 430 M - -
Net income 2021
7 903 M - -
Net cash position 2021
5 814 M - -
P/E ratio 2021
9,08x
Yield 2021
-
Sales 2022
12 561 M - -
Net income 2022
4 769 M - -
Net cash position 2022
11 197 M - -
P/E ratio 2022
14,2x
Yield 2022
-
Capitalization
66 409 M 66 409 M -
EV / Sales 2021
3,93x
EV / Sales 2022
4,40x
Nbr of Employees
9 766
Free-Float
81,9%
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis,...
Ratings of Regeneron Pharmaceuticals
All news about REGENERON PHARMACEUTICALS
12/03 Regeneron to Participate in H.C. Wainwright & Co. Virtual Event PR
12/03 Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL.. AQ
12/02 What COVID-19 vaccine and drug makers have to say about Omicron RE
12/02 MarketScreener's World Press Review - December 2, 2021 11/30 Officials offer vaccine reassurance; WHO advises against travel bans RE
11/30 US Stocks Slump as Omicron Variant, Fed Chief's Comment on Faster Asset Purchase Taperi.. MT
11/30 CLOSE UPDATE : US Stocks See Sharp Decline as Omicron Variant, Fed Chief Comment on Faster..MT
11/30 Yen, Swiss franc rally on global outlook risks after hawkish Powell RE
11/30 ANALYSIS : As Omicron plays havoc with markets, shares of vaccine makers surgeRE
11/30 Wall St sinks as taper acceleration worries pile onto virus angst RE
11/30 Pharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op.. MT
11/30 Equities Drop Midday as Moderna CEO Questions COVID-19 Vaccines' Efficacy Against Omicr.. MT
11/30 MIDDAY REPORT : US Stocks Drop as Moderna CEO Questions COVID-19 Vaccines' Efficacy Agains..MT
11/30 US Stocks Drop as Moderna CEO Warns on Efficacy of COVID-19 Vaccines Against Omicron; O.. MT
11/30 Wall St drops over 1% on Powell's faster taper comments, Omicron worries RE
News in other languages on REGENERON PHARMACEUTICALS
Analyst Recommendations on REGENERON PHARMACEUTICALS
Officials offer vaccine reassurance; WHO advises against travel bans
Chart REGENERON PHARMACEUTICALS
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends REGENERON PHARMACEUTICALS
Short Term Mid-Term Long Term Trends Bullish Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
635,16 $
Average target price
697,52 $
Spread / Average Target
9,82%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
